CD8A and neoplasm: Hence, in vivo CAP treatment inhibits the expansion and effective functions of cytotoxic tumor-infiltrating CD8+T cells (CTLs) via elevating the PD-1/PD-L1 immune checkpoint signaling level, thereby resulting in tumor immune escape.